Former Seagen CEO's biotech raises $140M series A to ready PD1/VEGFR2 antibody for clinic

Two months after former Seagen CEO David Epstein unveiled his new project, the biotech has secured "over" $140 million in series A funds to push forward its potential Keytruda contender.

Ottimo was born in 2020 out of a collaboration between investment firm Medicxi and biotech entrepreneur Jonny Finlay. Medicxi participated in today's series A fundraise along with RTW Investments, Decheng Capital, Janus Henderson Investors, J.P. Morgan Life Sciences Private Capital and Invus. The round was led by OrbiMed, Avoro Capital and Samsara BioCapital.